Navigation Links
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Date:11/12/2012

osis and one death, a myocardial infarction secondary to community-acquired pneumonia, were reported in the I.V. golimumab group.  Through week 52, the proportions of infusions and patients with infusion reactions were 0.7 percent and 3.6 percent, respectively, (versus 1.1 percent and 3.5 percent at week 24, respectively).

About GO-FURTHER
The GO-FURTHER trial is a Phase 3, international multicenter, double-blind, placebo-controlled study including 592 adults with RA designed to compare ACR 20 response at week 14 in patients receiving an I.V. golimumab infusion  plus methotrexate compared with patients receiving placebo infusions plus methotrexate. The trial included patients diagnosed with active RA who had at least six tender and six swollen joints and who had been receiving background methotrexate for at least three months. Patients were randomized 2:1 to receive a 30 (+/- 10) minute I.V. infusion of golimumab  2 mg/kg or placebo plus methotrexate at weeks 0, 4, and then every eight weeks.  The primary endpoint of the study was ACR 20 at week 14.  At week 16, patients receiving placebo with less than 10 percent improvement in combined swollen and tender joint counts were entered into early escape to receive I.V. golimumab 2 mg/kg at week 16 and week 20.  All patients receiving placebo crossed over to I.V. golimumab at week 24. Radiographs of the hands and feet were taken at baseline, week 24 (week 16 for early escape participants) and week 52 and were scored using the modified vdHS score.  Week 24 results from the Janssen-sponsored study were presented earlier this year at the 2012 EULAR Annual Congress and also appeared in the Annals of the Rheumatic Diseases.

About Rheumatoid Arthritis 
Rheumatoid Arthr
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
(Date:7/14/2014)... , July 14, 2014 BioAdaptives, Inc. ... , Chairman has assumed the roles of President and ... of Ferris Holding, Inc., the company that licensed its ... and its financial supporter. "Mr. ... our early transition as a privately held entity to ...
(Date:7/13/2014)... 13, 2014 Auf ... Tokio veranstalteten F&E-Tagung meldete Astellas ... Neuausrichtung seines Forschungsrahmenprogramms. Die Tagung bot Astellas ... fortgeschrittenen klinischen Programme und die Konzernstrategie des ... bestand darin, aktuelle Meldungen zu den Astellas-Initiativen ...
Breaking Medicine Technology:Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3BioAdaptives Prepares for Next Step 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4
... Calif., Nov. 14 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... devices,for the minimally invasive treatment of venous reflux ... using the VNUS,ClosureFAST catheter were presented today at ... VNUS ClosureFAST(TM) catheter is an endovenous,radiofrequency (RF) ablation ...
... Multi-national study compared FORTEO and the currently ... the treatment of Glucocorticoid-Induced Osteoporosis, INDIANAPOLIS, ... The New England Journal of Medicine, showed ... 1-34, teriparatide [rDNA,origin] injection) significantly increased lumbar ...
Cached Medicine Technology:Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium 2Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium 3FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 2FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 3FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 4FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 5FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 6
(Date:7/14/2014)... 14, 2014 The Cabin Chiang Mai, ... new Alumni Community website – a free ... help them maintain lifelong recovery wherever they live in ... clients the tools to help them maintain their recovery ... part of any reputable treatment programme. As a chronic ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... Protocol book review recently updated by Vkool.com, ... of a wide range of simple and ... endometriosis including:,     Increasing ... and dairy products ,     Increasing fiber ...
(Date:7/14/2014)... 2014 Reha Technology today announced ... portable and full-featured upper extremity robotic trainer that ... interactive games and challenges in a lightweight and ... , Armotion combines a variety of ... maximize the therapy effect for patients with severe ...
(Date:7/14/2014)... July 14, 2014 Love Digits LLC ... called Love Digits. The App brings ancient astrology to ... to quantify their compatibility using a five-star rating system. ... people can instantaneously test their compatibility for love and ... , The app’s five-star rating system generates a weighted ...
(Date:7/14/2014)... MT (PRWEB) July 14, 2014 New ... Women's Voices for the Earth examines toxic ... majority of women nationwide, including specific chemicals that may ... as additives and fragrances that may put women’s health ... science and research, Alexandra Scranton , the potential ...
Breaking Medicine News(10 mins):Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 3Health News:Reha Technology Launches the Armotion™, a Device for the Rehabilitation of the Upper Extremity 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5
... this country has nearly doubled in the past 20 years. ... therapists are charged with the task, but many are falling ... lack scientific rigor. This is in part because many of ... for-profit training centersare not grounded in science. A new ...
... , BOSTON, Oct. 2 Hess Corporation will present two $50,000 ... Foundation and the other to Children,s Hospital Boston,s Trauma Program -- ... Red Sox, home opening day. Aric Morrison, a Hess Retail regional ... , Hess Corporation promised to donate $500 for every home run ...
... award today for excellence in research, advancing oral health ... will receive the 2009 American Dental Association,s (ADA) Gold Medal ... formal presentation during a meeting of the ADA,s House ... once every three years, the award honors individuals who contribute ...
... highest honor on Kenneth L. Kalkwarf, D.D.S. at its 150th ... American Dental Association (ADA) will honor Kenneth L. Kalkwarf, D.D.S., ... Session and World Marketplace Exhibition in Honolulu. The Distinguished Service ... individual. , ADA President John S. Findley, D.D.S., ...
... 2 Beginning October 1st, The Peninsula Chicago will dedicate ... Month and several cancer research and education organizations. , "We ... cancer in some way and this is why we at ... Zec, general manager of The Peninsula Chicago. "In addition to ...
... 2 Pillar Capital is pleased to announce its acquisition ... to an order of the Bankruptcy Court for the District ... free and clear of claims. The Medico Labs business ... in 2000, manufactures and distributes private label and store brand ...
Cached Medicine News:Health News:Where's the science? The sorry state of psychotherapy 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 3Health News:ADA's 2009 Gold Medal Award Presentation Set for 150th Annual Session 2Health News:Dental Educator to Receive the ADA Distinguished Service Award 2Health News:Dental Educator to Receive the ADA Distinguished Service Award 3Health News:The Peninsula Chicago Gives Back During Breast Cancer Awareness Month 2Health News:Pillar Capital Announces Acquisition of Medico Labs' Assets 2
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... The Blue Line Wrist Control offers a ... wrist support for Carpal Tunnel Syndrome, tendinitis, ... the wrist. Careful design leaves fingers free ... wrist. Lightweight metal stay can be contoured ...
Combination Oppenheimer with Knuckle Bender - to dorsiflex wrist and flex MCP joints; includes two attachments to extend/flex distal finger joints....
Medicine Products: